<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39518964</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>21</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">11411</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms252111411</ELocationID><Abstract><AbstractText>IL-6 remains a key molecule of the cytokine storms characterizing COVID-19, exerting both proinflammatory and anti-inflammatory effects. Emerging research underscores the significance of IL-6 trans-signaling over classical signaling pathways, which has shifted the focus of therapeutic strategies. Additionally, the synergistic action of TNF-&#x3b1; and IFN-&#x3b3; has been found to induce inflammatory cell death through PANoptosis, further amplifying the severity of cytokine storms. Long COVID-19 patients, as well as those with cytokine storms triggered by other conditions, exhibit distinct laboratory profiles, indicating the need for targeted approaches to diagnosis and management. Growing evidence also highlights the gut microbiota's crucial role in modulating the immune response during COVID-19 by affecting cytokine production, adding further complexity to the disease's immunological landscape. Targeted intervention strategies should focus on specific cytokine cutoffs, though accurate cytokine quantification remains a clinical challenge. Current treatment strategies are increasingly focused on inhibiting IL-6 trans-signaling, which offers promise for more precise therapeutic approaches to manage hyperinflammatory responses in COVID-19. In light of recent discoveries, this review summarizes key research findings on cytokine storms, particularly their role in COVID-19 and other inflammatory conditions. It explores emerging therapeutic strategies targeting cytokines like IL-6, TNF-&#x3b1;, and IFN-&#x3b3;, while also addressing open questions, such as the need for better biomarkers to detect and manage cytokine storms. Additionally, the review highlights ongoing challenges in developing targeted treatments that mitigate hyperinflammation without compromising immune function, emphasizing the importance of continued research in this field.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paranga</LastName><ForeName>Tudorita Gabriela</ForeName><Initials>TG</Initials><Identifier Source="ORCID">0000-0002-8404-2771</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases (Internal Medicine II), Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Parascheva Clinical Hospital for Infectious Diseases, 700116 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitu</LastName><ForeName>Ivona</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2370-3166</Identifier><AffiliationInfo><Affiliation>Department of Morpho-Functional Sciences II, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavel-Tanasa</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2802-5993</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Immunology, St. Spiridon County Clinical Emergency Hospital, 700101 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosu</LastName><ForeName>Manuel Florin</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>St. Parascheva Clinical Hospital for Infectious Diseases, 700116 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine and Interdisciplinarity, Faculty of Medicine, University of Medicine and Pharmacy Grigore. T. Popa, 700115 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miftode</LastName><ForeName>Ionela-Larisa</ForeName><Initials>IL</Initials><Identifier Source="ORCID">0000-0003-4131-1019</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases (Internal Medicine II), Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Parascheva Clinical Hospital for Infectious Diseases, 700116 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Constantinescu</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0732-3745</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Immunology, St. Spiridon County Clinical Emergency Hospital, 700101 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obreja</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5807-6548</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases (Internal Medicine II), Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Parascheva Clinical Hospital for Infectious Diseases, 700116 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plesca</LastName><ForeName>Claudia Elena</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0009-0002-5704-578X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases (Internal Medicine II), Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Parascheva Clinical Hospital for Infectious Diseases, 700116 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miftode</LastName><ForeName>Egidia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases (Internal Medicine II), Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Parascheva Clinical Hospital for Infectious Diseases, 700116 Iasi, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>158/2022</GrantID><Agency>Grigore T. Popa University of Medicine and Pharmacy of Iasi</Agency><Country/></Grant><Grant><GrantID>POC/448/1/1/127606 CENEMED project no. 367/390043/2021</GrantID><Agency>Grigore T. Popa University of Medicine and Pharmacy of Iasi</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="Y">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="Y">Interleukin-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IFN-&#x3b3;</Keyword><Keyword MajorTopicYN="N">IL-6</Keyword><Keyword MajorTopicYN="N">TNF-&#x3b1;</Keyword><Keyword MajorTopicYN="N">cytokine storm</Keyword><Keyword MajorTopicYN="N">tocilizumab</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>9</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39518964</ArticleId><ArticleId IdType="pmc">PMC11547016</ArticleId><ArticleId IdType="doi">10.3390/ijms252111411</ArticleId><ArticleId IdType="pii">ijms252111411</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fajgenbaum D.C., June C.H. Cytokine Storm. N. Engl. J. Med. 2020;383:2255&#x2013;2273. doi: 10.1056/NEJMra2026131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki R., Kanneganti T.-D. The &#x201c;Cytokine Storm&#x201d;: Molecular Mechanisms and Therapeutic Prospects. Trends Immunol. 2021;42:681&#x2013;705. doi: 10.1016/j.it.2021.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2021.06.001</ArticleId><ArticleId IdType="pmc">PMC9310545</ArticleId><ArticleId IdType="pubmed">34217595</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatenoud L., Ferran C., Legendre C., Thouard I., Merite S., Reuter A., Gevaert Y., Kreis H., Franchimont P., Bach J.F. In Vivo Cell Activation following OKT3 Administration. Systemic Cytokine Release and Modulation by Corticosteroids. Transplantation. 1990;49:697&#x2013;702. doi: 10.1097/00007890-199004000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007890-199004000-00009</ArticleId><ArticleId IdType="pubmed">2109379</ArticleId></ArticleIdList></Reference><Reference><Citation>Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., Panoskaltsis N. Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. N. Engl. J. Med. 2006;355:1018&#x2013;1028. doi: 10.1056/NEJMoa063842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa063842</ArticleId><ArticleId IdType="pubmed">16908486</ArticleId></ArticleIdList></Reference><Reference><Citation>Paranga T.G., Pavel-Tanasa M., Constantinescu D., Plesca C.E., Petrovici C., Miftode I.-L., Moscalu M., Cianga P., Miftode E.G. Comparison of C-Reactive Protein with Distinct Hyperinflammatory Biomarkers in Association with COVID-19 Severity, Mortality and SARS-CoV-2 Variants. Front. Immunol. 2023;14:1213246. doi: 10.3389/fimmu.2023.1213246.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1213246</ArticleId><ArticleId IdType="pmc">PMC10302717</ArticleId><ArticleId IdType="pubmed">37388734</ArticleId></ArticleIdList></Reference><Reference><Citation>Paranga T.G., Pavel-tanasa M., Constantinescu D., Iftimi E., Plesca C.E., Miftode I., Cianga P., Miftode E. Distinct Soluble Immune Checkpoint pro Fi Les Characterize COVID-19 Severity, Mortality and SARS-CoV-2 Variant Infections. Front. Immunol. 2024;15:1464480. doi: 10.3389/fimmu.2024.1464480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1464480</ArticleId><ArticleId IdType="pmc">PMC11456479</ArticleId><ArticleId IdType="pubmed">39376569</ArticleId></ArticleIdList></Reference><Reference><Citation>Cron R.Q., Goyal G., Chatham W.W. Cytokine Storm Syndrome. Annu. Rev. Med. 2023;74:321&#x2013;337. doi: 10.1146/annurev-med-042921-112837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-042921-112837</ArticleId><ArticleId IdType="pubmed">36228171</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y., Zuo X., Zhang S., Ouyang Z., Jiang S., Wang F., Wang G. The Mechanism Behind Influenza Virus Cytokine Storm. Viruses. 2021;13:1362. doi: 10.3390/v13071362.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13071362</ArticleId><ArticleId IdType="pmc">PMC8310017</ArticleId><ArticleId IdType="pubmed">34372568</ArticleId></ArticleIdList></Reference><Reference><Citation>Ombrello M.J., Schulert G.S. COVID-19 and Cytokine Storm Syndrome: Are There Lessons from Macrophage Activation Syndrome? Transl. Res. 2021;232:1&#x2013;12. doi: 10.1016/j.trsl.2021.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2021.03.002</ArticleId><ArticleId IdType="pmc">PMC7934701</ArticleId><ArticleId IdType="pubmed">33684592</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V. Toll-like Receptors in Sepsis-Associated Cytokine Storm and Their Endogenous Negative Regulators as Future Immunomodulatory Targets. Int. Immunopharmacol. 2020;89:107087. doi: 10.1016/j.intimp.2020.107087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107087</ArticleId><ArticleId IdType="pmc">PMC7550173</ArticleId><ArticleId IdType="pubmed">33075714</ArticleId></ArticleIdList></Reference><Reference><Citation>Eloseily E.M., Cron R.Q. Bacteria-Associated Cytokine Storm Syndrome. Adv. Exp. Med. Biol. 2024;1448:275&#x2013;283. doi: 10.1007/978-3-031-59815-9_19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-031-59815-9_19</ArticleId><ArticleId IdType="pubmed">39117821</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterba G., Sterba Y. Parasitic and Fungal Triggers of Cytokine Storm Syndrome. Adv. Exp. Med. Biol. 2024;1448:293&#x2013;305. doi: 10.1007/978-3-031-59815-9_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-031-59815-9_21</ArticleId><ArticleId IdType="pubmed">39117823</ArticleId></ArticleIdList></Reference><Reference><Citation>Canna S.W., Cron R.Q. Highways to Hell: Mechanism-Based Management of Cytokine Storm Syndromes. J. Allergy Clin. Immunol. 2020;146:949&#x2013;959. doi: 10.1016/j.jaci.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7522622</ArticleId><ArticleId IdType="pubmed">33007328</ArticleId></ArticleIdList></Reference><Reference><Citation>Caricchio R., Gallucci S. Systemic Lupus Erythematosus and Cytokine Storm. Adv. Exp. Med. Biol. 2024;1448:355&#x2013;364. doi: 10.1007/978-3-031-59815-9_24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-031-59815-9_24</ArticleId><ArticleId IdType="pubmed">39117826</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng J., Ma Y., Jia J., Wang M., Teng J., Shi H., Liu H., Su Y., Ye J., Sun Y., et al. Cytokine Storm in Coronavirus Disease 2019 and Adult-Onset Still&#x2019;s Disease: Similarities and Differences. Front. Immunol. 2020;11:603389. doi: 10.3389/fimmu.2020.603389.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.603389</ArticleId><ArticleId IdType="pmc">PMC7856388</ArticleId><ArticleId IdType="pubmed">33552062</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsoukas P., Yeung R.S.M. Kawasaki Disease-Associated Cytokine Storm Syndrome. Adv. Exp. Med. Biol. 2024;1448:365&#x2013;383. doi: 10.1007/978-3-031-59815-9_25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-031-59815-9_25</ArticleId><ArticleId IdType="pubmed">39117827</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum D.C., Uldrick T.S., Bagg A., Frank D., Wu D., Srkalovic G., Simpson D., Liu A.Y., Menke D., Chandrakasan S., et al. International, Evidence-Based Consensus Diagnostic Criteria for HHV-8-Negative/Idiopathic Multicentric Castleman Disease. Blood. 2017;129:1646&#x2013;1657. doi: 10.1182/blood-2016-10-746933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-10-746933</ArticleId><ArticleId IdType="pmc">PMC5364342</ArticleId><ArticleId IdType="pubmed">28087540</ArticleId></ArticleIdList></Reference><Reference><Citation>Yongzhi X. COVID-19-Associated Cytokine Storm Syndrome and Diagnostic Principles: An Old and New Issue. Emerg. Microbes Infect. 2021;10:266&#x2013;276. doi: 10.1080/22221751.2021.1884503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1884503</ArticleId><ArticleId IdType="pmc">PMC7894425</ArticleId><ArticleId IdType="pubmed">33522893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes A.D., Teachey D.T., Diorio C. Riding the Storm: Managing Cytokine-Related Toxicities in CAR-T Cell Therapy. Semin. Immunopathol. 2024;46:5. doi: 10.1007/s00281-024-01013-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-024-01013-w</ArticleId><ArticleId IdType="pmc">PMC11252192</ArticleId><ArticleId IdType="pubmed">39012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Hines M.R., Knight T.E., McNerney K.O., Leick M.B., Jain T., Ahmed S., Frigault M.J., Hill J.A., Jain M.D., Johnson W.T., et al. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome. Transplant. Cell. Ther. 2023;29:e1&#x2013;e438. doi: 10.1016/j.jtct.2023.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtct.2023.03.006</ArticleId><ArticleId IdType="pmc">PMC10330221</ArticleId><ArticleId IdType="pubmed">36906275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarjian H., Stein A., G&#xf6;kbuget N., Fielding A.K., Schuh A.C., Ribera J.-M., Wei A., Dombret H., Fo&#xe0; R., Bassan R., et al. Blinatumomab Versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N. Engl. J. Med. 2017;376:836&#x2013;847. doi: 10.1056/NEJMoa1609783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1609783</ArticleId><ArticleId IdType="pmc">PMC5881572</ArticleId><ArticleId IdType="pubmed">28249141</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarczak D., Nierhaus A. Cytokine Storm-Definition, Causes, and Implications. Int. J. Mol. Sci. 2022;23:11740. doi: 10.3390/ijms231911740.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911740</ArticleId><ArticleId IdType="pmc">PMC9570384</ArticleId><ArticleId IdType="pubmed">36233040</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukan N. &#x201c;Cytokine Storm&#x201d;, Not Only in COVID-19 Patients. Mini-Review. Immunol. Lett. 2020;228:38&#x2013;44. doi: 10.1016/j.imlet.2020.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2020.09.007</ArticleId><ArticleId IdType="pmc">PMC7524442</ArticleId><ArticleId IdType="pubmed">33007369</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazier T., Hogue C.J.R., Bonney E.A., Yount K.M., Pearce B.D. Weathering the Storm; a Review of Pre-Pregnancy Stress and Risk of Spontaneous Abortion. Psychoneuroendocrinology. 2018;92:142&#x2013;154. doi: 10.1016/j.psyneuen.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2018.03.001</ArticleId><ArticleId IdType="pubmed">29628283</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao D., Yang R., Liu S., Ge D., Su X. Study on the Characteristics of Early Cytokine Storm Response to Cardiac Surgery. J. Interf. Cytokine Res. Off. J. Int. Soc. Interf. Cytokine Res. 2023;43:351&#x2013;358. doi: 10.1089/jir.2023.0044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2023.0044</ArticleId><ArticleId IdType="pubmed">37566476</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing A., Xu J., Meng W., Rosenfeld A.M., Li E.Y., Wertheim G., Paessler M., Bagg A., Frank D., Tan K., et al. Transcriptome and Unique Cytokine Microenvironment of Castleman Disease. Mod. Pathol. Off. J. United States Can. Acad. Pathol. Inc. 2022;35:451&#x2013;461. doi: 10.1038/s41379-021-00950-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41379-021-00950-3</ArticleId><ArticleId IdType="pmc">PMC9272352</ArticleId><ArticleId IdType="pubmed">34686774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Jiang M., Chen X., Montaner L.J. Cytokine Storm and Leukocyte Changes in Mild versus Severe SARS-CoV-2 Infection: Review of 3939 COVID-19 Patients in China and Emerging Pathogenesis and Therapy Concepts. J. Leukoc. Biol. 2020;108:17&#x2013;41. doi: 10.1002/JLB.3COVR0520-272R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3COVR0520-272R</ArticleId><ArticleId IdType="pmc">PMC7323250</ArticleId><ArticleId IdType="pubmed">32534467</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharra R., Sharma A.K., Datta S. Emerging Aspects of Cytokine Storm in COVID-19: The Role of Proinflammatory Cytokines and Therapeutic Prospects. Cytokine. 2023;169:156287. doi: 10.1016/j.cyto.2023.156287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2023.156287</ArticleId><ArticleId IdType="pmc">PMC10291296</ArticleId><ArticleId IdType="pubmed">37402337</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C., Wong P., Klein J., Castro T.B.R., Silva J., Sundaram M., Ellingson M.K., Mao T., Oh J.E., Israelow B., et al. Longitudinal Analyses Reveal Immunological Misfiring in Severe COVID-19. Nature. 2020;584:463&#x2013;469. doi: 10.1038/s41586-020-2588-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Huang S., Yin L. The Cytokine Storm and COVID-19. J. Med. Virol. 2021;93:250&#x2013;256. doi: 10.1002/jmv.26232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26232</ArticleId><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Song P., Li W., Xie J., Hou Y., You C. Cytokine Storm Induced by SARS-CoV-2. Clin. Chim. Acta. 2020;509:280&#x2013;287. doi: 10.1016/j.cca.2020.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.06.017</ArticleId><ArticleId IdType="pmc">PMC7283076</ArticleId><ArticleId IdType="pubmed">32531256</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Tang G., Liu Y., Zhang L., Chen B., Han Y., Fu Z., Wang L., Hu G., Ma Q., et al. The Role of IL-6 in Coronavirus, Especially in COVID-19. Front. Pharmacol. 2022;13:1033674. doi: 10.3389/fphar.2022.1033674.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.1033674</ArticleId><ArticleId IdType="pmc">PMC9727200</ArticleId><ArticleId IdType="pubmed">36506506</ArticleId></ArticleIdList></Reference><Reference><Citation>Grebenciucova E., VanHaerents S. Interleukin 6: At the Interface of Human Health and Disease. Front. Immunol. 2023;14:1255533. doi: 10.3389/fimmu.2023.1255533.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1255533</ArticleId><ArticleId IdType="pmc">PMC10569068</ArticleId><ArticleId IdType="pubmed">37841263</ArticleId></ArticleIdList></Reference><Reference><Citation>Forcina L., Franceschi C., Musar&#xf2; A. The Hormetic and Hermetic Role of IL-6. Ageing Res. Rev. 2022;80:101697. doi: 10.1016/j.arr.2022.101697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2022.101697</ArticleId><ArticleId IdType="pubmed">35850167</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose-John S., Jenkins B.J., Garbers C., Moll J.M., Scheller J. Targeting IL-6 Trans-Signalling: Past, Present and Future Prospects. Nat. Rev. Immunol. 2023;23:666&#x2013;681. doi: 10.1038/s41577-023-00856-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00856-y</ArticleId><ArticleId IdType="pmc">PMC10108826</ArticleId><ArticleId IdType="pubmed">37069261</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsour M., Croci D.M., Agazzi S., Borlongan C.V. Contemplating IL-6, a Double-Edged Sword Cytokine: Which Side to Use for Stroke Pathology? CNS Neurosci. Ther. 2023;29:493&#x2013;497. doi: 10.1111/cns.14041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.14041</ArticleId><ArticleId IdType="pmc">PMC9873516</ArticleId><ArticleId IdType="pubmed">36478506</ArticleId></ArticleIdList></Reference><Reference><Citation>Du P., Geng J., Wang F., Chen X., Huang Z., Wang Y. Role of IL-6 Inhibitor in Treatment of COVID-19-Related Cytokine Release Syndrome. Int. J. Med. Sci. 2021;18:1356&#x2013;1362. doi: 10.7150/ijms.53564.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.53564</ArticleId><ArticleId IdType="pmc">PMC7893562</ArticleId><ArticleId IdType="pubmed">33628091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasanvand A. COVID-19 and the Role of Cytokines in This Disease. Inflammopharmacology. 2022;30:789&#x2013;798. doi: 10.1007/s10787-022-00992-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-00992-2</ArticleId><ArticleId IdType="pmc">PMC9064717</ArticleId><ArticleId IdType="pubmed">35505267</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotaeva A.A., Samoilova E.V., Pogosova N.V., Kuchiev D.T., Gomyranova N.V., Paleev F.N. Factors of Interleukin-6 Signaling in COVID-19 Patients with Lung Damage of Varying Degrees: A Pilot Study. Bull. Exp. Biol. Med. 2024;176:772&#x2013;775. doi: 10.1007/s10517-024-06106-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10517-024-06106-y</ArticleId><ArticleId IdType="pubmed">38890212</ArticleId></ArticleIdList></Reference><Reference><Citation>Drost C.C., Rovas A., Osiaevi I., Schughart K., Lukasz A., Linke W.A., Pavenst&#xe4;dt H., K&#xfc;mpers P. Interleukin-6 Drives Endothelial Glycocalyx Damage in COVID-19 and Bacterial Sepsis. Angiogenesis. 2024;27:411&#x2013;422. doi: 10.1007/s10456-024-09916-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10456-024-09916-w</ArticleId><ArticleId IdType="pmc">PMC11303473</ArticleId><ArticleId IdType="pubmed">38598083</ArticleId></ArticleIdList></Reference><Reference><Citation>Qidwai T. Cytokine Storm in COVID-19 and Malaria: Annals of pro-Inflammatory Cytokines. Cytokine. 2024;173:156420. doi: 10.1016/j.cyto.2023.156420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2023.156420</ArticleId><ArticleId IdType="pubmed">37976701</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzaroni M.G., Piantoni S., Masneri S., Garrafa E., Martini G., Tincani A., Andreoli L., Franceschini F. Coagulation Dysfunction in COVID-19: The Interplay between Inflammation, Viral Infection and the Coagulation System. Blood Rev. 2021;46:100745. doi: 10.1016/j.blre.2020.100745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2020.100745</ArticleId><ArticleId IdType="pmc">PMC7444609</ArticleId><ArticleId IdType="pubmed">32868115</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavillegrand J.-R., Garnier M., Spaeth A., Mario N., Hariri G., Pilon A., Berti E., Fieux F., Thietart S., Urbina T., et al. Elevated Plasma IL-6 and CRP Levels Are Associated with Adverse Clinical Outcomes and Death in Critically Ill SARS-CoV-2 Patients: Inflammatory Response of SARS-CoV-2 Patients. Ann. Intensive Care. 2021;11:9. doi: 10.1186/s13613-020-00798-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-020-00798-x</ArticleId><ArticleId IdType="pmc">PMC7804215</ArticleId><ArticleId IdType="pubmed">33439360</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliyu M., Zohora F.T., Anka A.U., Ali K., Maleknia S., Saffarioun M., Azizi G. Interleukin-6 Cytokine: An Overview of the Immune Regulation, Immune Dysregulation, and Therapeutic Approach. Int. Immunopharmacol. 2022;111:109130. doi: 10.1016/j.intimp.2022.109130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.109130</ArticleId><ArticleId IdType="pubmed">35969896</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlini V., Noonan D.M., Abdalalem E., Goletti D., Sansone C., Calabrone L., Albini A. The Multifaceted Nature of IL-10: Regulation, Role in Immunological Homeostasis and Its Relevance to Cancer, COVID-19 and Post-COVID Conditions. Front. Immunol. 2023;14:1161067. doi: 10.3389/fimmu.2023.1161067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1161067</ArticleId><ArticleId IdType="pmc">PMC10287165</ArticleId><ArticleId IdType="pubmed">37359549</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Qahtani A.A., Alhamlan F.S., Al-Qahtani A.A. Pro-Inflammatory and Anti-Inflammatory Interleukins in Infectious Diseases: A Comprehensive Review. Trop. Med. Infect. Dis. 2024;9:13. doi: 10.3390/tropicalmed9010013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed9010013</ArticleId><ArticleId IdType="pmc">PMC10818686</ArticleId><ArticleId IdType="pubmed">38251210</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M., Rabaan A.A., Alwarthan S., Alhajri M., Halwani M.A., Alshengeti A., Najim M.A., Alwashmi A.S.S., Alshehri A.A., Alshamrani S.A., et al. Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID. Vaccines. 2023;11:699. doi: 10.3390/vaccines11030699.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030699</ArticleId><ArticleId IdType="pmc">PMC10059134</ArticleId><ArticleId IdType="pubmed">36992283</ArticleId></ArticleIdList></Reference><Reference><Citation>Nara H., Watanabe R. Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism. Int. J. Mol. Sci. 2021;22:9889. doi: 10.3390/ijms22189889.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22189889</ArticleId><ArticleId IdType="pmc">PMC8471880</ArticleId><ArticleId IdType="pubmed">34576053</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.Y.C., Hoiland R.L., Stukas S., Wellington C.L., Sekhon M.S. Confronting the Controversy: Interleukin-6 and the COVID-19 Cytokine Storm Syndrome. Eur. Respir. J. 2020;56:2003006. doi: 10.1183/13993003.03006-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03006-2020</ArticleId><ArticleId IdType="pmc">PMC7474149</ArticleId><ArticleId IdType="pubmed">32883678</ArticleId></ArticleIdList></Reference><Reference><Citation>Plocque A., Mitri C., Lef&#xe8;vre C., Tabary O., Touqui L., Philippart F. Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far? Drugs. 2023;83:1&#x2013;36. doi: 10.1007/s40265-022-01803-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-022-01803-2</ArticleId><ArticleId IdType="pmc">PMC9743129</ArticleId><ArticleId IdType="pubmed">36508116</ArticleId></ArticleIdList></Reference><Reference><Citation>Khafaei M., Asghari R., Zafari F., Sadeghi M. Impact of IL-6 Rs1800795 and IL-17A Rs2275913 Gene Polymorphisms on the COVID-19 Prognosis and Susceptibility in a Sample of Iranian Patients. Cytokine. 2024;174:156445. doi: 10.1016/j.cyto.2023.156445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2023.156445</ArticleId><ArticleId IdType="pubmed">38056249</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X., Tang K., Wang Z., He S., Luo Z. Impacts of Inflammatory Cytokines Variants on Systemic Inflammatory Profile and COVID-19 Severity. J. Epidemiol. Glob. Health. 2024;14:363&#x2013;378. doi: 10.1007/s44197-024-00204-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44197-024-00204-w</ArticleId><ArticleId IdType="pmc">PMC11176143</ArticleId><ArticleId IdType="pubmed">38376765</ArticleId></ArticleIdList></Reference><Reference><Citation>Noureddine R., Baba H., Aqillouch S., Abounouh K., Laazaazia O., Elmessaoudi-Idrissi M., Bahmani F.Z., Tanouti I.A., Ouladlahsen A., Sarih M., et al. The Interleukin-6 Gene Variants May Protect against SARS-CoV-2 Infection and the Severity of COVID-19: A Case-Control Study in a Moroccan Population. BMC Med. Genom. 2024;17:139. doi: 10.1186/s12920-024-01911-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-024-01911-w</ArticleId><ArticleId IdType="pmc">PMC11112821</ArticleId><ArticleId IdType="pubmed">38783290</ArticleId></ArticleIdList></Reference><Reference><Citation>Zawawi Z.M., Kalyanasundram J., Zain R.M., Thayan R., Basri D.F., Yap W.B. Prospective Roles of Tumor Necrosis Factor-Alpha (TNF-&#x3b1;) in COVID-19: Prognosis, Therapeutic and Management. Int. J. Mol. Sci. 2023;24:6142. doi: 10.3390/ijms24076142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24076142</ArticleId><ArticleId IdType="pmc">PMC10094668</ArticleId><ArticleId IdType="pubmed">37047115</ArticleId></ArticleIdList></Reference><Reference><Citation>van Loo G., Bertrand M.J.M. Death by TNF: A Road to Inflammation. Nat. Rev. Immunol. 2023;23:289&#x2013;303. doi: 10.1038/s41577-022-00792-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00792-3</ArticleId><ArticleId IdType="pmc">PMC9665039</ArticleId><ArticleId IdType="pubmed">36380021</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., Liu J., Zhang D., Xu Z., Ji J., Wen C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Front Immunol. 2020;11:1708. doi: 10.3389/fimmu.2020.01708.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01708</ArticleId><ArticleId IdType="pmc">PMC7365923</ArticleId><ArticleId IdType="pubmed">32754163</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle D.M., Kim-Schulze S., Huang H.-H., Beckmann N.D., Nirenberg S., Wang B., Lavin Y., Swartz T.H., Madduri D., Stock A., et al. An Inflammatory Cytokine Signature Predicts COVID-19 Severity and Survival. Nat. Med. 2020;26:1636&#x2013;1643. doi: 10.1038/s41591-020-1051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Halim C., Mirza A.F., Sari M.I. The Association between TNF-&#x3b1;, IL-6, and Vitamin D Levels and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis. Pathogens. 2022;11:195. doi: 10.3390/pathogens11020195.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020195</ArticleId><ArticleId IdType="pmc">PMC8879207</ArticleId><ArticleId IdType="pubmed">35215138</ArticleId></ArticleIdList></Reference><Reference><Citation>Lighter J., Phillips M., Hochman S., Sterling S., Johnson D., Francois F., Stachel A. Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. Clin. Infect. Dis. 2020;71:896&#x2013;897. doi: 10.1093/cid/ciaa415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa415</ArticleId><ArticleId IdType="pmc">PMC7184372</ArticleId><ArticleId IdType="pubmed">32271368</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng K.I., Gao F., Wang X.-B., Sun Q.-F., Pan K.-H., Wang T.-Y., Ma H.-L., Chen Y.-P., Liu W.-Y., George J., et al. Letter to the Editor: Obesity as a Risk Factor for Greater Severity of COVID-19 in Patients with Metabolic Associated Fatty Liver Disease. Microorganism. 2020;108:154244. doi: 10.1016/j.metabol.2020.154244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2020.154244</ArticleId><ArticleId IdType="pmc">PMC7166301</ArticleId><ArticleId IdType="pubmed">32320741</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., Wu Y., Zhang L., Yu Z., Fang M., et al. Clinical Course and Outcomes of Critically Ill Patients with SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study. Lancet Respir. Med. 2020;8:475&#x2013;481. doi: 10.1016/S2213-2600(20)30079-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30079-5</ArticleId><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Balzanelli M.G., Distratis P., Lazzaro R., Cefalo A., Catucci O., Aityan S.K., Dipalma G., Vimercati L., Inchingolo A.D., Maggiore M.E., et al. The Vitamin D, IL-6 and the EGFR Markers a Possible Way to Elucidate the Lung-Heart-Kidney Cross-Talk in COVID-19 Disease: A Foregone Conclusion. Microorganisms. 2021;9:1903. doi: 10.3390/microorganisms9091903.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9091903</ArticleId><ArticleId IdType="pmc">PMC8464828</ArticleId><ArticleId IdType="pubmed">34576798</ArticleId></ArticleIdList></Reference><Reference><Citation>Udomsinprasert W., Jittikoon J., Sangroongruangsri S., Chaikledkaew U. Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-Analysis. J. Clin. Immunol. 2021;41:11&#x2013;22. doi: 10.1007/s10875-020-00899-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-020-00899-z</ArticleId><ArticleId IdType="pmc">PMC7602765</ArticleId><ArticleId IdType="pubmed">33128665</ArticleId></ArticleIdList></Reference><Reference><Citation>Karki R., Sharma B.R., Tuladhar S., Williams E.P., Zalduondo L., Samir P., Zheng M., Sundaram B., Banoth B., Malireddi R.K.S., et al. Synergism of TNF-&#x3b1; and IFN-&#x3b3; Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell. 2021;184:149. doi: 10.1016/j.cell.2020.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.025</ArticleId><ArticleId IdType="pmc">PMC7674074</ArticleId><ArticleId IdType="pubmed">33278357</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldesouki R.E., Kishk R.M., Abd El-Fadeal N.M., Mahran R.I., Kamel N., Riad E., Nemr N., Kishk S.M., Mohammed E.A.-M. Association of IL-10-592 C&#x2009;&gt;&#x2009;A /-1082 A&#x2009;&gt;&#x2009;G and the TNF&#x3b1; -308 G&#x2009;&gt;&#x2009;A with Susceptibility to COVID-19 and Clinical Outcomes. BMC Med. Genom. 2024;17:40. doi: 10.1186/s12920-023-01793-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-023-01793-4</ArticleId><ArticleId IdType="pmc">PMC10826193</ArticleId><ArticleId IdType="pubmed">38287362</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyrillou K., Burzynski L.C., Clarke M.C.H. Alternative Pathways of IL-1 Activation, and Its Role in Health and Disease. Front. Immunol. 2020;11:613170. doi: 10.3389/fimmu.2020.613170.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.613170</ArticleId><ArticleId IdType="pmc">PMC7775495</ArticleId><ArticleId IdType="pubmed">33391283</ArticleId></ArticleIdList></Reference><Reference><Citation>Makaremi S., Asgarzadeh A., Kianfar H., Mohammadnia A., Asghariazar V., Safarzadeh E. The Role of IL-1 Family of Cytokines and Receptors in Pathogenesis of COVID-19. Inflamm. Res. 2022;71:923&#x2013;947. doi: 10.1007/s00011-022-01596-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-022-01596-w</ArticleId><ArticleId IdType="pmc">PMC9243884</ArticleId><ArticleId IdType="pubmed">35751653</ArticleId></ArticleIdList></Reference><Reference><Citation>Nezhad M.G., Jami G., Kooshkaki O., Chamani S., Naghizadeh A. The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical) J. Interferon Cytokine Res. 2023;43:147&#x2013;163. doi: 10.1089/jir.2022.0185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2022.0185</ArticleId><ArticleId IdType="pubmed">37062817</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;cke J., Heinrich F., Malsy J., Meins N., Schnell J., B&#xf6;ttcher M., Nawrocki M., Zhang T., Bertram F., Sabihi M., et al. Intestinal IL-1&#x3b2; Plays a Role in Protecting against SARS-CoV-2 Infection. J. Immunol. 2023;211:1052&#x2013;1061. doi: 10.4049/jimmunol.2200844.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2200844</ArticleId><ArticleId IdType="pmc">PMC10476162</ArticleId><ArticleId IdType="pubmed">37556130</ArticleId></ArticleIdList></Reference><Reference><Citation>Qudus M.S., Tian M., Sirajuddin S., Liu S., Afaq U., Wali M., Liu J., Pan P., Luo Z., Zhang Q., et al. The Roles of Critical Pro-inflammatory Cytokines in the Drive of Cytokine Storm During SARS-CoV-2 Infection. J. Med. Virol. 2023;95:e28751. doi: 10.1002/jmv.28751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28751</ArticleId><ArticleId IdType="pubmed">37185833</ArticleId></ArticleIdList></Reference><Reference><Citation>Costela-Ruiz V.J., Illescas-Montes R., Puerta-Puerta J.M., Ruiz C., Melguizo-Rodr&#xed;guez L. SARS-CoV-2 Infection: The Role of Cytokines in COVID-19 Disease. Cytokine Growth Factor Rev. 2020;54:62&#x2013;75. doi: 10.1016/j.cytogfr.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7265853</ArticleId><ArticleId IdType="pubmed">32513566</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C., Willscher E., Paschold L., Gottschick C., Klee B., Henkes S.-S., Bosurgi L., Dutzmann J., Sedding D., Frese T., et al. The IL-1&#x3b2;, IL-6, and TNF Cytokine Triad Is Associated with Post-Acute Sequelae of COVID-19. Cell Rep. Med. 2022;3:100663. doi: 10.1016/j.xcrm.2022.100663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes S.M.R., de Brito A.C.S., Manfro W.F.P., Ribeiro-Alves M., de Ribeiro R.S.A., da Cal M.S., da Lisboa V.C., de Abreu D.P.B., Castilho L.D.R., de Porto L.C.M.S., et al. High Levels of Pro-Inflammatory SARS-CoV-2-Specific Biomarkers Revealed by In Vitro Whole Blood Cytokine Release Assay (CRA) in Recovered and Long-COVID-19 Patients. PLoS ONE. 2023;18:e0283983. doi: 10.1371/journal.pone.0283983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0283983</ArticleId><ArticleId IdType="pmc">PMC10075475</ArticleId><ArticleId IdType="pubmed">37018291</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso-Dom&#xed;nguez J., Gallego-Rodr&#xed;guez M., Mart&#xed;nez-Barros I., Calder&#xf3;n-Cruz B., Leiro-Fern&#xe1;ndez V., P&#xe9;rez-Gonz&#xe1;lez A., Poveda E. High Levels of IL-1&#x3b2;, TNF-&#x3b1; and MIP-1&#x3b1; One Month after the Onset of the Acute SARS-CoV-2 Infection, Predictors of Post COVID-19 in Hospitalized Patients. Microorganisms. 2023;11:2396. doi: 10.3390/microorganisms11102396.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11102396</ArticleId><ArticleId IdType="pmc">PMC10609568</ArticleId><ArticleId IdType="pubmed">37894054</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Chen C. Gut Microbiota, Inflammatory Proteins and COVID-19: A Mendelian Randomisation Study. Front. Immunol. 2024;15:1406291. doi: 10.3389/fimmu.2024.1406291.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1406291</ArticleId><ArticleId IdType="pmc">PMC11128586</ArticleId><ArticleId IdType="pubmed">38803488</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovanetti M., Pannella G., Altomare A., Rocchi G., Guarino M., Ciccozzi M., Riva E., Gherardi G. Exploring the Interplay between COVID-19 and Gut Health: The Potential Role of Prebiotics and Probiotics in Immune Support. Viruses. 2024;16:370. doi: 10.3390/v16030370.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16030370</ArticleId><ArticleId IdType="pmc">PMC10975078</ArticleId><ArticleId IdType="pubmed">38543736</ArticleId></ArticleIdList></Reference><Reference><Citation>Keely S., Talley N.J., Hansbro P.M. Pulmonary-Intestinal Cross-Talk in Mucosal Inflammatory Disease. Mucosal Immunol. 2012;5:7&#x2013;18. doi: 10.1038/mi.2011.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2011.55</ArticleId><ArticleId IdType="pmc">PMC3243663</ArticleId><ArticleId IdType="pubmed">22089028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancona G., Alagna L., Alteri C., Palomba E., Tonizzo A., Pastena A., Muscatello A., Gori A., Bandera A. Gut and Airway Microbiota Dysbiosis and Their Role in COVID-19 and Long-COVID. Front. Immunol. 2023;14:1080043. doi: 10.3389/fimmu.2023.1080043.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1080043</ArticleId><ArticleId IdType="pmc">PMC10030519</ArticleId><ArticleId IdType="pubmed">36969243</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzello F., Viciani E., Gionchetti P., Filippone E., Imbesi V., Melotti L., Dussias N.K., Salice M., Santacroce B., Padella A., et al. Signatures of Disease Outcome Severity in the Intestinal Fungal and Bacterial Microbiome of COVID-19 Patients. Front. Cell. Infect. Microbiol. 2024;14:1352202. doi: 10.3389/fcimb.2024.1352202.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2024.1352202</ArticleId><ArticleId IdType="pmc">PMC10952111</ArticleId><ArticleId IdType="pubmed">38510960</ArticleId></ArticleIdList></Reference><Reference><Citation>Essex M., Pascual-Leone B.M., L&#xf6;ber U., Kuhring M., Zhang B., Br&#xfc;ning U., Fritsche-Guenther R., Krzanowski M., Vernengo F.F., Brumhard S., et al. Gut Microbiota Dysbiosis Is Associated with Altered Tryptophan Metabolism and Dysregulated Inflammatory Response in COVID-19. NPJ Biofilms Microbiomes. 2024;10:66. doi: 10.1038/s41522-024-00538-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41522-024-00538-0</ArticleId><ArticleId IdType="pmc">PMC11291933</ArticleId><ArticleId IdType="pubmed">39085233</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Lau R.I., Liu Q., Su Q., Chan F.K.L., Ng S.C. Gut Microbiota in COVID-19: Key Microbial Changes, Potential Mechanisms and Clinical Applications. Nat. Rev. Gastroenterol. Hepatol. 2023;20:323&#x2013;337. doi: 10.1038/s41575-022-00698-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-022-00698-4</ArticleId><ArticleId IdType="pmc">PMC9589856</ArticleId><ArticleId IdType="pubmed">36271144</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh Y.K., Zuo T., Lui G.C.-Y., Zhang F., Liu Q., Li A.Y., Chung A.C., Cheung C.P., Tso E.Y., Fung K.S., et al. Gut Microbiota Composition Reflects Disease Severity and Dysfunctional Immune Responses in Patients with COVID-19. Gut. 2021;70:698&#x2013;706. doi: 10.1136/gutjnl-2020-323020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323020</ArticleId><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron L.B., Dweep H., Yin X., Wang H., Damra M., Goldman A.R., Gorman N., Palmer C.S., Tang H.-Y., Shaikh M.W., et al. Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients. Front. Immunol. 2021;12:686240. doi: 10.3389/fimmu.2021.686240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.686240</ArticleId><ArticleId IdType="pmc">PMC8219958</ArticleId><ArticleId IdType="pubmed">34177935</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata N., Takeuchi T., Masuoka H., Aoki R., Ishikane M., Iwamoto N., Sugiyama M., Suda W., Nakanishi Y., Terada-Hirashima J., et al. Human Gut Microbiota and Its Metabolites Impact Immune Responses in COVID-19 and Its Complications. Gastroenterology. 2023;164:272&#x2013;288. doi: 10.1053/j.gastro.2022.09.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.09.024</ArticleId><ArticleId IdType="pmc">PMC9499989</ArticleId><ArticleId IdType="pubmed">36155191</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Wan Y., Zuo T., Yeoh Y.K., Liu Q., Zhang L., Zhan H., Lu W., Xu W., Lui G.C.Y., et al. Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19. Gastroenterology. 2022;162:548&#x2013;561.e4. doi: 10.1053/j.gastro.2021.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.10.013</ArticleId><ArticleId IdType="pmc">PMC8529231</ArticleId><ArticleId IdType="pubmed">34687739</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Wang B., Chen T., Wang H., Liu J., Zhao X., Zhang Y. Two New and Effective Food-Extracted Immunomodulatory Agents Exhibit Anti-Inflammatory Response Activity in the HACE2 Acute Lung Injury Murine Model of COVID-19. Front. Immunol. 2024;15:1374541. doi: 10.3389/fimmu.2024.1374541.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1374541</ArticleId><ArticleId IdType="pmc">PMC11130445</ArticleId><ArticleId IdType="pubmed">38807598</ArticleId></ArticleIdList></Reference><Reference><Citation>Cione E., Siniscalchi A., Gangemi P., Cosco L., Colosimo M., Longhini F., Luciani F., De Sarro G., Berrino L., D&#x2019;Agostino B., et al. Neuron-Specific Enolase Serum Levels in COVID-19 Are Related to the Severity of Lung Injury. PLoS ONE. 2021;16:e0251819. doi: 10.1371/journal.pone.0251819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0251819</ArticleId><ArticleId IdType="pmc">PMC8133450</ArticleId><ArticleId IdType="pubmed">34010310</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y., Cheng C., Zheng X., Jin Y., Duan G., Chen M., Chen S. Elevated Procalcitonin Is Positively Associated with the Severity of COVID-19: A Meta-Analysis Based on 10 Cohort Studies. Medicina. 2021;57:594. doi: 10.3390/medicina57060594.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57060594</ArticleId><ArticleId IdType="pmc">PMC8227321</ArticleId><ArticleId IdType="pubmed">34207689</ArticleId></ArticleIdList></Reference><Reference><Citation>SB M.J., Chacko B., Selvarajan S., Peter J.V., Geevar T., Dave R.G., Georgy J.T., Zachariah A., George T., Sathyendra S., et al. Biomarkers of Coagulation, Endothelial, Platelet Function, and Fibrinolysis in Patients with COVID-19: A Prospective Study. Sci. Rep. 2024;14:2011. doi: 10.1038/s41598-024-51908-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-51908-9</ArticleId><ArticleId IdType="pmc">PMC10805716</ArticleId><ArticleId IdType="pubmed">38263377</ArticleId></ArticleIdList></Reference><Reference><Citation>Metkus T.S., Sokoll L.J., Barth A.S., Czarny M.J., Hays A.G., Lowenstein C.J., Michos E.D., Nolley E.P., Post W.S., Resar J.R., et al. Myocardial Injury in Severe COVID-19 Compared with Non-COVID-19 Acute Respiratory Distress Syndrome. Circulation. 2021;143:553&#x2013;565. doi: 10.1161/CIRCULATIONAHA.120.050543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.050543</ArticleId><ArticleId IdType="pmc">PMC7864609</ArticleId><ArticleId IdType="pubmed">33186055</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., Gong W., Liu X., Liang J., Zhao Q., et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802&#x2013;810. doi: 10.1001/jamacardio.2020.0950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.0950</ArticleId><ArticleId IdType="pmc">PMC7097841</ArticleId><ArticleId IdType="pubmed">32211816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochoa-Ram&#xed;rez L.A., De la Herr&#xe1;n Arita A.K., Sanchez-Zazueta J.G., R&#xed;os-Burgue&#xf1;o E., Murillo-Llanes J., De Jes&#xfa;s-Gonz&#xe1;lez L.A., Farfan-Morales C.N., Cordero-Rivera C.D., Del &#xc1;ngel R.M., Romero-Utrilla A., et al. Association between Lipid Profile and Clinical Outcomes in COVID-19 Patients. Sci. Rep. 2024;14:12139. doi: 10.1038/s41598-024-62899-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-62899-y</ArticleId><ArticleId IdType="pmc">PMC11130121</ArticleId><ArticleId IdType="pubmed">38802549</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar A., Sanyal S., Majumdar A., Tewari D.N., Bhattacharjee U., Pal J., Chakrabarti A.K., Dutta S. Development of Lab Score System for Predicting COVID-19 Patient Severity: A Retrospective Analysis. PLoS ONE. 2022;17:e0273006. doi: 10.1371/journal.pone.0273006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0273006</ArticleId><ArticleId IdType="pmc">PMC9462772</ArticleId><ArticleId IdType="pubmed">36084080</ArticleId></ArticleIdList></Reference><Reference><Citation>Antunez Mui&#xf1;os P.J., L&#xf3;pez Otero D., Amat-Santos I.J., L&#xf3;pez Pa&#xed;s J., Aparisi A., Cacho Antonio C.E., Catal&#xe1; P., Gonz&#xe1;lez Ferrero T., Cabez&#xf3;n G., Otero Garc&#xed;a O., et al. The COVID-19 Lab Score: An Accurate Dynamic Tool to Predict in-Hospital Outcomes in COVID-19 Patients. Sci. Rep. 2021;11:9361. doi: 10.1038/s41598-021-88679-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88679-6</ArticleId><ArticleId IdType="pmc">PMC8087839</ArticleId><ArticleId IdType="pubmed">33931677</ArticleId></ArticleIdList></Reference><Reference><Citation>Statsenko Y., Al Zahmi F., Habuza T., Gorkom K.N.-V., Zaki N. Prediction of COVID-19 Severity Using Laboratory Findings on Admission: Informative Values, Thresholds, ML Model Performance. BMJ Open. 2021;11:e044500. doi: 10.1136/bmjopen-2020-044500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-044500</ArticleId><ArticleId IdType="pmc">PMC7918887</ArticleId><ArticleId IdType="pubmed">33637550</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendland P., Schmitt V., Zimmermann J., H&#xe4;ger L., G&#xf6;pel S., Schenkel-H&#xe4;ger C., Kschischo M. Machine Learning Models for Predicting Severe COVID-19 Outcomes in Hospitals. Inform. Med. Unlocked. 2023;37:101188. doi: 10.1016/j.imu.2023.101188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imu.2023.101188</ArticleId><ArticleId IdType="pmc">PMC9890886</ArticleId><ArticleId IdType="pubmed">36742350</ArticleId></ArticleIdList></Reference><Reference><Citation>Laatifi M., Douzi S., Ezzine H., El Asry C., Naya A., Bouklouze A., Zaid Y., Naciri M. Explanatory Predictive Model for COVID-19 Severity Risk Employing Machine Learning, Shapley Addition, and LIME. Sci. Rep. 2023;13:5481. doi: 10.1038/s41598-023-31542-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-31542-7</ArticleId><ArticleId IdType="pmc">PMC10071246</ArticleId><ArticleId IdType="pubmed">37015978</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashidi H.H., Ikram A., Dang L.T., Bashir A., Zohra T., Ali A., Tanvir H., Mudassar M., Ravindran R., Akhtar N., et al. Comparing Machine Learning Screening Approaches Using Clinical Data and Cytokine Profiles for COVID-19 in Resource-Limited and Resource-Abundant Settings. Sci. Rep. 2024;14:14892. doi: 10.1038/s41598-024-63707-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-63707-3</ArticleId><ArticleId IdType="pmc">PMC11211475</ArticleId><ArticleId IdType="pubmed">38937503</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabaro S., D&#x2019;Esposito V., Di Matola T., Sale S., Cennamo M., Terracciano D., Parisi V., Oriente F., Portella G., Beguinot F., et al. Cytokine Signature and COVID-19 Prediction Models in the Two Waves of Pandemics. Sci. Rep. 2021;11:20793. doi: 10.1038/s41598-021-00190-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-00190-0</ArticleId><ArticleId IdType="pmc">PMC8531346</ArticleId><ArticleId IdType="pubmed">34675240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawerkamp H.C., Dyer A.H., Patil N.D., McElheron M., O&#x2019;Dowd N., O&#x2019;Doherty L., Mhaonaigh A.U., George A.M., O&#x2019;Halloran A.M., Reddy C., et al. Characterisation of the Pro-Inflammatory Cytokine Signature in Severe COVID-19. Front. Immunol. 2023;14:1170012. doi: 10.3389/fimmu.2023.1170012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1170012</ArticleId><ArticleId IdType="pmc">PMC10101230</ArticleId><ArticleId IdType="pubmed">37063871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalinina O., Golovkin A., Zaikova E., Aquino A., Bezrukikh V., Melnik O., Vasilieva E., Karonova T., Kudryavtsev I., Shlyakhto E. Cytokine Storm Signature in Patients with Moderate and Severe COVID-19. Int. J. Mol. Sci. 2022;23:8879. doi: 10.3390/ijms23168879.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23168879</ArticleId><ArticleId IdType="pmc">PMC9408700</ArticleId><ArticleId IdType="pubmed">36012146</ArticleId></ArticleIdList></Reference><Reference><Citation>Maa&#xdf; H., Ynga-Durand M., Milo&#x161;evi&#x107; M., Krstanovi&#x107; F., Mate&#x161;i&#x107; M.P., &#x17d;u&#x17e;a I., Jonji&#x107; S., Brizi&#x107; I., &#x160;usti&#x107; A., Bloos F., et al. Serum Cytokine Dysregulation Signatures Associated with COVID-19 Outcomes in High Mortality Intensive Care Unit Cohorts across Pandemic Waves and Variants. Sci. Rep. 2024;14:13605. doi: 10.1038/s41598-024-64384-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-64384-y</ArticleId><ArticleId IdType="pmc">PMC11176334</ArticleId><ArticleId IdType="pubmed">38871772</ArticleId></ArticleIdList></Reference><Reference><Citation>Diorio C., Shaw P.A., Pequignot E., Orlenko A., Chen F., Aplenc R., Barrett D.M., Bassiri H., Behrens E., DiNofia A.M., et al. Diagnostic Biomarkers to Differentiate Sepsis from Cytokine Release Syndrome in Critically Ill Children. Blood Adv. 2020;4:5174&#x2013;5183. doi: 10.1182/bloodadvances.2020002592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020002592</ArticleId><ArticleId IdType="pmc">PMC7594400</ArticleId><ArticleId IdType="pubmed">33095872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessel C., Vollenberg R., Masjosthusmann K., Hinze C., Wittkowski H., Debaugnies F., Nagant C., Corazza F., V&#xe9;ly F., Kaplanski G., et al. Discrimination of COVID-19 From Inflammation-Induced Cytokine Storm Syndromes Using Disease-Related Blood Biomarkers. Arthritis Rheumatol. 2021;73:1791&#x2013;1799. doi: 10.1002/art.41763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41763</ArticleId><ArticleId IdType="pmc">PMC8251089</ArticleId><ArticleId IdType="pubmed">33880885</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood H., Jones J.R., Hui K., Mare T., Pirani T., Galloway J., Metaxa V., Benjamin R., Rutherford A., Cain S., et al. Secondary HLH Is Uncommon in Severe COVID-19. Br. J. Haematol. 2020;190:e283&#x2013;e285. doi: 10.1111/bjh.16934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16934</ArticleId><ArticleId IdType="pmc">PMC7307063</ArticleId><ArticleId IdType="pubmed">32526046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakim N.N., Chi J., Olazagasti C., Liu J.M. Secondary Hemophagocytic Lymphohistiocytosis versus Cytokine Release Syndrome in Severe COVID-19 Patients. Exp. Biol. Med. 2021;246:5&#x2013;9. doi: 10.1177/1535370220962043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370220962043</ArticleId><ArticleId IdType="pmc">PMC7797996</ArticleId><ArticleId IdType="pubmed">32972235</ArticleId></ArticleIdList></Reference><Reference><Citation>Onuk S., Sipahio&#x11f;lu H., Karahan S., Ye&#x15f;iltepe A., Kuzug&#xfc;den S., Karabulut A., Dursun Z.B., Ak&#x131;n A. Cytokine Levels and Severity of Illness Scoring Systems to Predict Mortality in COVID-19 Infection. Healthcare. 2023;11:387. doi: 10.3390/healthcare11030387.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare11030387</ArticleId><ArticleId IdType="pmc">PMC9914724</ArticleId><ArticleId IdType="pubmed">36766961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruytinx P., Vandormael P., Fraussen J., Pieters Z., Thonissen S., Hellings N., Stinissen P., Callebaut I., Penders J., Vanhove K., et al. Comprehensive Antibody and Cytokine Profiling in Hospitalized COVID-19 Patients in Relation to Clinical Outcomes in a Large Belgian Cohort. Sci. Rep. 2023;13:19322. doi: 10.1038/s41598-023-46421-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-46421-4</ArticleId><ArticleId IdType="pmc">PMC10630327</ArticleId><ArticleId IdType="pubmed">37935729</ArticleId></ArticleIdList></Reference><Reference><Citation>Copaescu A., Smibert O., Gibson A., Phillips E.J., Trubiano J.A. The Role of IL-6 and Other Mediators in the Cytokine Storm Associated with SARS-CoV-2 Infection. J. Allergy Clin. Immunol. 2020;146:518&#x2013;534.e1. doi: 10.1016/j.jaci.2020.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.07.001</ArticleId><ArticleId IdType="pmc">PMC7471766</ArticleId><ArticleId IdType="pubmed">32896310</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Li T., Han M., Li X., Wu D., Xu Y., Zhu Y., Liu Y., Wang X., Wang L. Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19. J. Med. Virol. 2020;92:791&#x2013;796. doi: 10.1002/jmv.25770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25770</ArticleId><ArticleId IdType="pmc">PMC7228247</ArticleId><ArticleId IdType="pubmed">32181911</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Chu D., Kalantar-Zadeh K., George J., Young H.A., Liu G. Cytokines: From Clinical Significance to Quantification. Adv. Sci. 2021;8:e2004433. doi: 10.1002/advs.202004433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202004433</ArticleId><ArticleId IdType="pmc">PMC8336501</ArticleId><ArticleId IdType="pubmed">34114369</ArticleId></ArticleIdList></Reference><Reference><Citation>Verberk I.M., Nossent E.J., Bontkes H.J., Teunissen C.E. Pre-Analytical Sample Handling Effects on Blood Cytokine Levels: Quality Control of a COVID-19 Biobank. Biomark. Med. 2021;15:987&#x2013;997. doi: 10.2217/bmm-2020-0770.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2020-0770</ArticleId><ArticleId IdType="pmc">PMC8359910</ArticleId><ArticleId IdType="pubmed">34289718</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen L., Keegan A., Melanson S.E.F., Walt D.R. Impact of Clinical Sample Handling and Processing on Ultra-Low Level Measurements of Plasma Cytokines. Clin. Biochem. 2019;65:38&#x2013;44. doi: 10.1016/j.clinbiochem.2019.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2019.01.001</ArticleId><ArticleId IdType="pubmed">30633878</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Z., Luo Y., Huang C., Wang Z., Song G., Pan Y., Zhao X., Liu S. An Intelligent Graphene-Based Biosensing Device for Cytokine Storm Syndrome Biomarkers Detection in Human Biofluids. Small. 2021;17:e2101508. doi: 10.1002/smll.202101508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smll.202101508</ArticleId><ArticleId IdType="pubmed">34110682</ArticleId></ArticleIdList></Reference><Reference><Citation>De Silva T., Fawzy M., Hasani A., Ghanbari H., Abnavi A., Askar A., Ling Y., Mohammadzadeh M.R., Kabir F., Ahmadi R., et al. Ultrasensitive Rapid Cytokine Sensors Based on Asymmetric Geometry Two-Dimensional MoS(2) Diodes. Nat. Commun. 2022;13:7593. doi: 10.1038/s41467-022-35278-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35278-2</ArticleId><ArticleId IdType="pmc">PMC9763493</ArticleId><ArticleId IdType="pubmed">36535944</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo-Alvarez E., D&#x2019;Alessandro S., Zanotta N., Basilico N., Parapini S., Signorini L., Perego F., Maina K.K., Ferrante P., Modenese A., et al. Multiplex Array Analysis of Circulating Cytokines and Chemokines in COVID-19 Patients during the First Wave of the SARS-CoV-2 Pandemic in Milan, Italy. BMC Immunol. 2024;25:49. doi: 10.1186/s12865-024-00641-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-024-00641-z</ArticleId><ArticleId IdType="pmc">PMC11282750</ArticleId><ArticleId IdType="pubmed">39061002</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo M.B., Romo A.M.N., Zafra A.G.S., Garrido J. de D.L.-G. Predictors of Mortality in Patients with COVID-19 by Flow Cytometry. Clin. Immunol. Commun. 2023;3:14&#x2013;20. doi: 10.1016/j.clicom.2023.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clicom.2023.02.003</ArticleId><ArticleId IdType="pmc">PMC9918322</ArticleId><ArticleId IdType="pubmed">38014400</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Li S., Liu J., Liang B., Wang X., Wang H., Li W., Tong Q., Yi J., Zhao L., et al. Longitudinal Characteristics of Lymphocyte Responses and Cytokine Profiles in the Peripheral Blood of SARS-CoV-2 Infected Patients. EBioMedicine. 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102763</ArticleId><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., et al. Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019. J. Clin. Investig. 2020;130:2620&#x2013;2629. doi: 10.1172/JCI137244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulhaq Z.S., Soraya G.V. Anti-IL-6 Receptor Antibody Treatment for Severe COVID-19 and the Potential Implication of IL-6 Gene Polymorphisms in Novel Coronavirus Pneumonia. Med. Clin. 2020;155:548&#x2013;556. doi: 10.1016/j.medcli.2020.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medcli.2020.07.002</ArticleId><ArticleId IdType="pmc">PMC7832797</ArticleId><ArticleId IdType="pubmed">33521302</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulhaq Z.S., Soraya G.V. Interleukin-6 as a Potential Biomarker of COVID-19 Progression. Med. Mal. Infect. 2020;50:382&#x2013;383. doi: 10.1016/j.medmal.2020.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medmal.2020.04.002</ArticleId><ArticleId IdType="pmc">PMC7129451</ArticleId><ArticleId IdType="pubmed">32259560</ArticleId></ArticleIdList></Reference><Reference><Citation>Balzanelli M.G., Distratis P., Lazzaro R., Pham V.H., Tran T.C., Dipalma G., Bianco A., Serlenga E.M., Aityan S.K., Pierangeli V., et al. Analysis of Gene Single Nucleotide Polymorphisms in COVID-19 Disease Highlighting the Susceptibility and the Severity towards the Infection. Diagnostics. 2022;12:2824. doi: 10.3390/diagnostics12112824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics12112824</ArticleId><ArticleId IdType="pmc">PMC9689844</ArticleId><ArticleId IdType="pubmed">36428884</ArticleId></ArticleIdList></Reference><Reference><Citation>Balzanelli M., Distratis P., Catucci O., Amatulli F., Cefalo A., Lazzaro R., Aityan K.S., Dalagni G., Nico A., De Michele A., et al. Clinical and Diagnostic Findings in COVID-19 Patients: An Original Research from SG Moscati Hospital in Taranto Italy. J. Biol. Regul. Homeost. Agents. 2021;35:171&#x2013;183. doi: 10.23812/20-605-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/20-605-A</ArticleId><ArticleId IdType="pubmed">33491346</ArticleId></ArticleIdList></Reference><Reference><Citation>Balzanelli M.G., Distratis P., Aityan S.K., Amatulli F., Catucci O., Cefalo A., De Michele A., Dipalma G., Inchingolo F., Lazzaro R., et al. An Alternative &#x201c;Trojan Horse&#x201d; Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology. Endocr. Metab. Immune Disord. Drug Targets. 2022;22:1&#x2013;5. doi: 10.2174/1871530321666210127141945.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871530321666210127141945</ArticleId><ArticleId IdType="pubmed">33504318</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Veerdonk F.L. COVID-19 Pneumonia and Cytokine Storm Syndrome. In: Cron R.Q., Behrens E.M., editors. Cytokine Storm Syndrome. Springer International Publishing; Cham, Switzerland: 2024. pp. 307&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">39117824</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Qu M., Zhou X., Zhao K., Lai C., Tang Q., Xian W., Chen R., Li X., Li Z., et al. The Timeline and Risk Factors of Clinical Progression of COVID-19 in Shenzhen, China. J. Transl. Med. 2020;18:270. doi: 10.1186/s12967-020-02423-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02423-8</ArticleId><ArticleId IdType="pmc">PMC7332535</ArticleId><ArticleId IdType="pubmed">32620125</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhimraj A., Morgan R.L., Shumaker A.H., Baden L.R., Cheng V.C.-C., Edwards K.M., Gallagher J.C., Gandhi R.T., Muller W.J., Nakamura M.M., et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022) Clin. Infect. Dis. 2024;78:e250&#x2013;e349. doi: 10.1093/cid/ciac724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac724</ArticleId><ArticleId IdType="pmc">PMC9494372</ArticleId><ArticleId IdType="pubmed">36063397</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentilotti E., Savoldi A., Compri M., G&#xf3;rska A., De Nardo P., Visentin A., Be G., Razzaboni E., Soriolo N., Meneghin D., et al. Assessment of COVID-19 Progression on Day 5 from Symptoms Onset. BMC Infect. Dis. 2021;21:883. doi: 10.1186/s12879-021-06596-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06596-5</ArticleId><ArticleId IdType="pmc">PMC8401365</ArticleId><ArticleId IdType="pubmed">34454452</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone J.H., Frigault M.J., Serling-Boyd N.J., Fernandes A.D., Harvey L., Foulkes A.S., Horick N.K., Healy B.C., Shah R., Bensaci A.M., et al. Efficacy of Tocilizumab in Patients Hospitalized with COVID-19. N. Engl. J. Med. 2020;383:2333&#x2013;2344. doi: 10.1056/NEJMoa2028836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028836</ArticleId><ArticleId IdType="pmc">PMC7646626</ArticleId><ArticleId IdType="pubmed">33085857</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvarani C., Dolci G., Massari M., Merlo D.F., Cavuto S., Savoldi L., Bruzzi P., Boni F., Braglia L., Turr&#xe0; C., et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern. Med. 2021;181:24&#x2013;31. doi: 10.1001/jamainternmed.2020.6615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.6615</ArticleId><ArticleId IdType="pmc">PMC7577199</ArticleId><ArticleId IdType="pubmed">33080005</ArticleId></ArticleIdList></Reference><Reference><Citation>Suresh K., Figart M., Formeck S., Mehmood T., Salam M.A., Bassilly D. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania. J. Investig. Med. High Impact Case Rep. 2021;9:23247096211019556. doi: 10.1177/23247096211019557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/23247096211019557</ArticleId><ArticleId IdType="pmc">PMC8193653</ArticleId><ArticleId IdType="pubmed">34105382</ArticleId></ArticleIdList></Reference><Reference><Citation>Salama C., Han J., Yau L., Reiss W.G., Kramer B., Neidhart J.D., Criner G.J., Kaplan-Lewis E., Baden R., Pandit L., et al. Tocilizumab in Patients Hospitalized with COVID-19 Pneumonia. N. Engl. J. Med. 2021;384:20&#x2013;30. doi: 10.1056/NEJMoa2030340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2030340</ArticleId><ArticleId IdType="pmc">PMC7781101</ArticleId><ArticleId IdType="pubmed">33332779</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar-Hari M., Vale C.L., Godolphin P.J., Fisher D., Higgins J.P.T., Spiga F., Savovic J., Tierney J., Baron G., Benbenishty J.S., et al. Association between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-Analysis. JAMA. 2021;326:499&#x2013;518. doi: 10.1001/jama.2021.11330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.11330</ArticleId><ArticleId IdType="pmc">PMC8261689</ArticleId><ArticleId IdType="pubmed">34228774</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rossi N., Scarpazza C., Filippini C., Cordioli C., Rasia S., Mancinelli C.R., Rizzoni D., Romanelli G., Cossi S., Vettoretto N., et al. Early Use of Low Dose Tocilizumab in Patients with COVID-19: A Retrospective Cohort Study with a Complete Follow-Up. EClinicalMedicine. 2020;25:100459. doi: 10.1016/j.eclinm.2020.100459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100459</ArticleId><ArticleId IdType="pmc">PMC7366117</ArticleId><ArticleId IdType="pubmed">32838235</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen F.D., RECOVERY Collaborative Group Baricitinib in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial and Updated Meta-Analysis. Lancet. 2022;400:359&#x2013;368. doi: 10.1016/S0140-6736(22)01109-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01109-6</ArticleId><ArticleId IdType="pmc">PMC9333998</ArticleId><ArticleId IdType="pubmed">35908569</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampitsakos T., Papaioannou O., Tsiri P., Katsaras M., Katsimpris A., Kalogeropoulos A.P., Malakounidou E., Zarkadi E., Tsirikos G., Georgiopoulou V., et al. Tocilizumab versus Baricitinib in Hospitalized Patients with Severe COVID-19: An Open Label, Randomized Controlled Trial. Clin. Microbiol. Infect. 2023;29:372&#x2013;378. doi: 10.1016/j.cmi.2022.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.10.015</ArticleId><ArticleId IdType="pmc">PMC9636985</ArticleId><ArticleId IdType="pubmed">36273769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunny S., Tran A., Lee J., Abdallah M., Chaudhry N., Quale J. Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients with COVID-19: Experience From a Public Hospital System in New York City. Open Forum Infect. Dis. 2023;10:ofad426. doi: 10.1093/ofid/ofad426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad426</ArticleId><ArticleId IdType="pmc">PMC10442059</ArticleId><ArticleId IdType="pubmed">37608917</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Fan X., Zhang X., Jiang F., Wu Y., Yang B., Li X., Liu D. Efficacy and Safety of Tocilizumab and Baricitinib among Patients Hospitalized for COVID-19: A Systematic Review and Meta-Analysis. Front. Pharmacol. 2023;14:1293331. doi: 10.3389/fphar.2023.1293331.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1293331</ArticleId><ArticleId IdType="pmc">PMC10703388</ArticleId><ArticleId IdType="pubmed">38074144</ArticleId></ArticleIdList></Reference><Reference><Citation>Dastan F., Jamaati H., Barati S., Varmazyar S., Yousefian S., Niknami E., Tabarsi P. The Effects of Combination-Therapy of Tocilizumab and Baricitinib on the Management of Severe COVID-19 Cases: A Randomized Open-Label Clinical Trial. Front. Pharmacol. 2023;14:1265541. doi: 10.3389/fphar.2023.1265541.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1265541</ArticleId><ArticleId IdType="pmc">PMC10620525</ArticleId><ArticleId IdType="pubmed">37927607</ArticleId></ArticleIdList></Reference><Reference><Citation>Miftode E., Miftode L., Coman I., Prepeliuc C., Obreja M., St&#x103;m&#x103;teanu O., P&#x103;r&#xe2;ng&#x103; T.G., Leca D., Ple&#x15f;ca C.E. Diabetes Mellitus-A Risk Factor for Unfavourable Outcome in COVID-19 Patients-The Experience of an Infectious Diseases Regional Hospital. Healthcare. 2021;9:788. doi: 10.3390/healthcare9070788.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare9070788</ArticleId><ArticleId IdType="pmc">PMC8306222</ArticleId><ArticleId IdType="pubmed">34201473</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothuizen L.E., Livio F., Buclin T. Drugs that aggravate the course of COVID-19: Really? Rev. Med. Suisse. 2020;16:852&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">32348052</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelleni M.T. ACEIs, ARBs, Ibuprofen Originally Linked to COVID-19: The Other Side of the Mirror. Inflammopharmacology. 2020;28:1477&#x2013;1480. doi: 10.1007/s10787-020-00755-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-020-00755-x</ArticleId><ArticleId IdType="pmc">PMC7486973</ArticleId><ArticleId IdType="pubmed">32920716</ArticleId></ArticleIdList></Reference><Reference><Citation>Smart L., Fawkes N., Goggin P., Pennick G., Rainsford K.D., Charlesworth B., Shah N. A Narrative Review of the Potential Pharmacological Influence and Safety of Ibuprofen on Coronavirus Disease 19 (COVID-19), ACE2, and the Immune System: A Dichotomy of Expectation and Reality. Inflammopharmacology. 2020;28:1141&#x2013;1152. doi: 10.1007/s10787-020-00745-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-020-00745-z</ArticleId><ArticleId IdType="pmc">PMC7427497</ArticleId><ArticleId IdType="pubmed">32797326</ArticleId></ArticleIdList></Reference><Reference><Citation>Laughey W., Lodhi I., Pennick G., Smart L., Sanni O., Sandhu S., Charlesworth B. Ibuprofen, Other NSAIDs and COVID-19: A Narrative Review. Inflammopharmacology. 2023;31:2147&#x2013;2159. doi: 10.1007/s10787-023-01309-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-023-01309-7</ArticleId><ArticleId IdType="pmc">PMC10518289</ArticleId><ArticleId IdType="pubmed">37603158</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushner P., McCarberg B.H., Grange L., Kolosov A., Haveric A.L., Zucal V., Petruschke R., Bissonnette S. The Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in COVID-19. NPJ Prim. Care Respir. Med. 2022;32:35. doi: 10.1038/s41533-022-00300-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41533-022-00300-z</ArticleId><ArticleId IdType="pmc">PMC9489480</ArticleId><ArticleId IdType="pubmed">36127354</ArticleId></ArticleIdList></Reference><Reference><Citation>Moshawih S., Jarrar Q., Bahrin A.A., Lim A.F., Ming L., Goh H.P. Evaluating NSAIDs in SARS-CoV-2: Immunomodulatory Mechanisms and Future Therapeutic Strategies. Heliyon. 2024;10:e25734. doi: 10.1016/j.heliyon.2024.e25734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e25734</ArticleId><ArticleId IdType="pmc">PMC10864964</ArticleId><ArticleId IdType="pubmed">38356603</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.S., Alfajaro M.M., Chow R.D., Wei J., Filler R.B., Eisenbarth S.C., Wilen C.B. Non-Steroidal Anti-Inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection. J. Virol. 2021;95:10-1128. doi: 10.1128/JVI.00014-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00014-21</ArticleId><ArticleId IdType="pmc">PMC8092681</ArticleId><ArticleId IdType="pubmed">33441348</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., Elmahi E., et al. Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med. 2021;384:693&#x2013;704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Hern&#xe1;ndez M.&#xc1;., Baena-Bustos M., Carneros D., Zurita-Palomo C., Mu&#xf1;oz-Pinillos P., Mill&#xe1;n J., Padillo F.J., Smerdou C., von Kobbe C., Rose-John S., et al. Targeting IL-6 Trans-Signalling by Sgp130Fc Attenuates Severity in SARS-CoV-2 -Infected Mice and Reduces Endotheliopathy. EBioMedicine. 2024;103:105132. doi: 10.1016/j.ebiom.2024.105132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2024.105132</ArticleId><ArticleId IdType="pmc">PMC11061249</ArticleId><ArticleId IdType="pubmed">38677182</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>